Table 4.
Univariate and multivariate logistic regression analysis for the predictors of pathological complete response.
| Factor | Univariate Analysis | Multivariate Analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||||
| Lower | Upper | Lower | Upper | ||||||
| Age | Years | 1.00 | 0.99 | 1.02 | 0.775 | ||||
| Menauposal status | Premen (RC) vs. postmen | 1.03 | 0.68 | 1.55 | 0.903 | ||||
| Clinical T stage | T3/4 (RC) vs. T1/2 | 1.87 | 1.10 | 3.16 | 0.020 | 2.16 | 1.10 | 4.23 | 0.025 |
| Clinical Node status | Positive (RC) vs. negative | 0.91 | 0.60 | 1.40 | 0.681 | ||||
| NLR | High (RC) vs. low | 1.83 | 1.12 | 2.98 | 0.016 | 0.96 | 0.46 | 2.00 | 0.909 |
| MLR | High (RC) vs. low | 2.06 | 1.32 | 3.21 | 0.002 | 1.11 | 0.61 | 2.03 | 0.735 |
| PLR | High (RC) vs. low | 2.16 | 1.34 | 3.48 | 0.002 | 1.80 | 0.95 | 3.44 | 0.074 |
| PIV | High (RC) vs. low | 3.80 | 2.21 | 6.52 | < 0.001 | 3.32 | 1.53 | 7.21 | 0.002 |
| ER status | Positive (RC) vs. negative | 5.63 | 3.62 | 8.75 | < 0.001 | 3.24 | 1.84 | 5.71 | < 0.001 |
| HER-2 status | Negative (RC) vs. positive | 3.64 | 2.35 | 5.63 | < 0.001 | 3.84 | 2.17 | 6.80 | < 0.001 |
| Ki-67 index | Low (RC) vs. high | 4.16 | 2.40 | 7.24 | < 0.001 | 3.30 | 1.72 | 6.32 | < 0.001 |
| Histopathology | IDC vs. other | 0.59 | 0.23 | 1.51 | 0.271 | ||||
| Chemotherapy | AplusT vs. other | 0.83 | 0.53 | 1.31 | 0.424 | ||||
OR odds ratio, CI confidential interval, RC reference category, NLR neutrophil-to-lymphocyte ratio, MLR monocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, PIV Pan-immune-inflammation-value, ER estrogen receptor, HER-2 human epidermal growth factor receptor-2, IDC invasive ductal carcinoma, AplusT anthracycline plus taxane.
The multivariate logistic regression model is significant (p < 0.001).
Bold numbers indicate statistical significance.